Biologics Resources News

>> Biologics Resources LLC (BRLLC) has secured exclusive license from the NIH to develop conjugate anthrax vaccine to induce dual antibodies (immunity) against both, capsule (responsible for initiation of infection by evading the host immune system), and toxins (responsible for toxemia and death). The capsules are poly-DL-Glutamic acid (PGA) a natural polymers that form protective sheath around the spores of gram-positive bacteria.

>> BRLLC is also in the process of securing license from N.I.H. for the development and production of humanized monoclonal antibodies against Bacillus anthracis capsule and toxins induced by the conjugate vaccine for pre-exposure and post-exposure prophylaxis.

>> BRLLC plans to exploit the PGA conjugate technology to develop countermeasures against other diseases caused by the capsule bearing bacteria such as hospital infections.